Actively Recruiting

Phase Not Applicable
Age: 80Years +
All Genders
NCT07403760

Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly

Led by Beijing Anzhen Hospital · Updated on 2026-02-11

182

Participants Needed

1

Research Sites

152 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The WISER-AF trial is a multicenter, double-blind, sham-controlled, randomized controlled trial. It aims to evaluate the efficacy and safety of catheter ablation compared to a sham procedure in improving the quality of life (SF-36 score) in very elderly patients (aged ≥80 years) with symptomatic atrial fibrillation over a 6-month follow-up period.

CONDITIONS

Official Title

Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly

Who Can Participate

Age: 80Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 80 years or older
  • Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment
  • Symptomatic atrial fibrillation including palpitations, chest tightness, fatigue, dizziness, blackouts, or shortness of breath
  • Voluntary participation with signed informed consent
Not Eligible

You will not qualify if you...

  • New York Heart Association Class IV heart failure
  • Acute myocardial infarction, cardiac surgery, or percutaneous coronary intervention within the past year
  • Long-standing persistent atrial fibrillation lasting longer than 1 year
  • Left atrial anteroposterior diameter greater than 6 cm
  • History of prior atrial fibrillation ablation
  • Atrial fibrillation caused by reversible conditions such as post-surgery, infection, or hyperthyroidism
  • Severe mitral stenosis
  • Moderate to severe liver failure (Child-Pugh class B or C)
  • Severe kidney failure (stage 4 or 5) or ongoing dialysis
  • Inability to cooperate due to dementia or severe mental disorder
  • Presence of left atrial thrombus
  • Previous left atrial appendage occlusion
  • Contraindications to anticoagulation
  • Life expectancy less than 1 year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Beijing, China

Actively Recruiting

Loading map...

Research Team

L

Liu He, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here